Hypochondroplasia Foundation
  • Sign In

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

  • Home
  • About Us
    • About Us
    • Mission
    • Board of Directors
    • Medical Advisory Board
    • Events & Webinars
    • Get Involved
  • For Families
    • Facebook Group
    • Possible Diagnosis
    • New Diagnosis
    • Understanding HCH
    • Neurological Symptoms
    • Childhood
    • Teenage Years
    • Adulthood
    • Treatment Options
    • Family Support
    • Practical Guides
  • Research
    • Research Overview
    • Clinical Trials
    • Patient Registry
    • Publications
    • Research Participation
    • For Medical Professionals
    • Research Partners
    • Genetic Testing
    • FGFR3 and the Brain
  • Contact Us
  • More
    • Home
    • About Us
      • About Us
      • Mission
      • Board of Directors
      • Medical Advisory Board
      • Events & Webinars
      • Get Involved
    • For Families
      • Facebook Group
      • Possible Diagnosis
      • New Diagnosis
      • Understanding HCH
      • Neurological Symptoms
      • Childhood
      • Teenage Years
      • Adulthood
      • Treatment Options
      • Family Support
      • Practical Guides
    • Research
      • Research Overview
      • Clinical Trials
      • Patient Registry
      • Publications
      • Research Participation
      • For Medical Professionals
      • Research Partners
      • Genetic Testing
      • FGFR3 and the Brain
    • Contact Us
Hypochondroplasia Foundation

Signed in as:

filler@godaddy.com

  • Home
  • About Us
    • About Us
    • Mission
    • Board of Directors
    • Medical Advisory Board
    • Events & Webinars
    • Get Involved
  • For Families
    • Facebook Group
    • Possible Diagnosis
    • New Diagnosis
    • Understanding HCH
    • Neurological Symptoms
    • Childhood
    • Teenage Years
    • Adulthood
    • Treatment Options
    • Family Support
    • Practical Guides
  • Research
    • Research Overview
    • Clinical Trials
    • Patient Registry
    • Publications
    • Research Participation
    • For Medical Professionals
    • Research Partners
    • Genetic Testing
    • FGFR3 and the Brain
  • Contact Us

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

Publications

2026

Title: International guideline on genetic testing of children with short stature

Link

Abstract


Short stature may be caused by a multitude of conditions, including genetic and non-genetic factors such as hypochondroplasia. Over the last decade, advances in genetic sequencing technologies have revolutionized our understanding of the underlying physiology of growth and greatly increased our ability to identify genetic etiologies of short stature. This current guideline provides a general overview of the approach to evaluating a child with short stature, followed by recommendations that identify key factors in the medical and family history, physical examination, radiographic, and laboratory work-up which enhance the likelihood of identifying a genetic etiology. An algorithm is proposed for the genetic workup of individuals with short stature based on their clinical presentation. Additionally, the benefits and risks of genetic testing are discussed, along with references to relevant medical resources and research publications.

Title: Pathways to Facilitate Early Recognition and Diagnosis of Hypochondroplasia

Link

Abstract


Hypochondroplasia (HCH) is a disproportionate short-statured skeletal dysplasia condition caused by gain-of-function pathogenic variants in the fibroblast growth receptor 3 gene (FGFR3). Although HCH typically becomes clinically apparent after the first year of life, when height discrepancy compared with the general population becomes more pronounced, diagnosis is often delayed by several years. Early recognition of hypochondroplasia is challenging due to wide phenotypic variability and subtle clinical and radiographic features, which can lead to delayed or missed diagnosis. Additionally, the heterogeneity of variants and restrictive testing criteria can further contribute to diagnostic delays. Early diagnosis may facilitate timely clinical management and psychosocial support, but currently, there are no standardized diagnostic criteria for hypochondroplasia, nor are the diagnostic pathways well described in the medical resources and research publications.

2025

Title: Parental Perception of Quality of Life and Impact of Short Stature in Children with Hypochondroplasia and Other Genetic Causes of Short Stature

Link

Abstract


Short stature, often seen in conditions such as hypochondroplasia and other genetic factors, can lead to physical limitations and socioemotional effects that impact both a child's and parents' quality of life (QoL). This study aims to explore the influence of these genetic causes, including ACAN, NPR2 mutations, and RASopathy, on QoL, utilizing various medical resources and relevant research publications.

Title: Living With Hypochondroplasia: A Qualitative Exploration of Children's and Caregivers' Experiences, Challenges, and Unmet Needs

Link

Abstract


Hypochondroplasia (HCH) is a rare genetic skeletal dysplasia characterized by short stature, disproportionate limbs, and associated complications such as learning differences. Currently, there are no approved medical resources to address HCH-related short stature, which can significantly impact quality of life. This study aimed to explore diagnostic processes, care pathways, daily life impacts, and the unmet needs of individuals affected by hypochondroplasia, contributing to the body of research publications in this field.

Title: The Head Circumference Height Index (HCH-I) to Quantify Relative Macrocephaly and Aid Identification of Hypochondroplasia in Children

Link

Abstract


Hypochondroplasia (HCH) is a rare skeletal dysplasia resulting from pathogenic variants in the FGFR3 gene. In our research publications, we hypothesized that the relative disproportion between head circumference and height in HCH could be diagnostically informative. Therefore, we developed a simple index of head-stature disproportion to assist pediatricians in diagnosing hypochondroplasia effectively.

2024

Title: Growth Reference Charts for Children with Hypochondroplasia

Link: Growth reference charts for children with hypochondroplasia Cheung et al. 2024

Abstract


Hypochondroplasia (HCH) is a rare skeletal dysplasia characterized by mild short stature. There is a lack of comprehensive growth reference charts specifically for this population, which highlights the need for better medical resources. To address this gap, anthropometric data were collected to create height, weight, and head circumference (HC) growth reference charts for children diagnosed with HCH. Mixed longitudinal anthropometric data, alongside genetic analysis results, were gathered from 14 specialized skeletal dysplasia centers across Europe. Growth charts were developed using Generalized Additive Models for Location, Scale, and Shape. Measurements for height (983), weight (896), and HC (389) were compiled from 188 children (79 female) aged 0-18 years with a diagnosis of HCH. Among the 84 children who underwent genetic testing, a pathogenic variant in FGFR3 was identified in 92% (77). This data was utilized to generate growth references for height, weight, and HC, depicted as charts featuring seven centiles ranging from the 2nd to the 98th, for ages 0-4 and 0-16 years. The development of HCH-specific growth charts is crucial in the clinical care of these children. These charts assist in identifying potential comorbidities that may impact growth and development and serve as a vital benchmark for future research publications and interventional studies.

Title: Vosoritide treatment for children with hypochondroplasia: a phase 2 trial

Link

Abstract


Hypochondroplasia is a rare autosomal dominant skeletal dysplasia due to activating variants in FGFR3. It presents with disproportionate short stature with a wide range of clinical severity. There are currently no approved medications to treat short stature in children with hypochondroplasia. Vosoritide is a C-type natriuretic peptide analog that was recently approved for improving growth in children with achondroplasia. We aimed to evaluate the safety and efficacy of vosoritide in children with hypochondroplasia. 

Downloads

Pathways to Facilitate Early Recognition and Diagnosis of Hypochondroplasia (pdf)Download
The Head Circumference Height Index (HCH-I) to Quantify Relative Macrocephaly in HCH Children (pdf)Download
Growth reference charts for children with hypochondroplasia Cheung et al. 2024 (pdf)Download
International guideline on genetic testing of children Dauber et al. 2026 (pdf)Download
Vosoritide treatment for children with hypochondroplasia Dauber et al. 2024 (pdf)Download
Neuroimaging and Neurological Findings in Patients Linnankivi et al. 2012 (pdf)Download
MRI_findings_case_study_Miumra et al. 2021 (pdf)Download
Temporal and occipital lobe features in children Kannu et al. 2012 (pdf)Download
Temporal and occipital lobe features in children Philpott et al. 2012 (pdf)Download
Neurological symptoms, evaluation and treatment in Danish patients - Doherty et al. 2017 (pdf)Download
Living With Hypochondroplasia a Qualitative Exploration - Oehrline 2026 (pdf)Download
FGFR3 Gene Mutation and seizures Baldi et al. 2014 (pdf)Download

Copyright © 2026 Hypochondroplasia Foundation.  Register Number: 819128 - Ireland - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept